Welcome to our dedicated page for Axogen SEC filings (Ticker: AXGN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Axogen, Inc. filings document a Nasdaq-listed operating company focused on peripheral nerve repair technologies and related surgical products. Form 8-K reports furnish quarterly and annual operating results, Regulation FD investor presentations, FDA-related disclosures for Avance® (acellular nerve allograft-arwx), and material agreements tied to common stock financing and shelf registration activity.
Proxy materials describe shareholder voting matters, board governance, executive compensation, equity awards, and pay-versus-performance disclosures. The filing record also identifies Axogen’s common stock structure and corporate governance framework, while event reports record officer compensation arrangements, regulatory language for Avance, and other formal updates to the company’s public disclosure record.
Axogen, Inc. is the subject of an amended Schedule 13G filing by First Light Asset Management, LLC and Mathew P. Arens. First Light Asset Management may be deemed the beneficial owner of 3,746,380 shares of Axogen common stock, representing 6.97% of the class.
Mathew P. Arens may be deemed the beneficial owner of 4,072,910 shares, or 7.58% of the class, through his control of the Manager, direct ownership of 187,000 shares, and 139,530 shares in a joint account. Most voting and dispositive power is shared through the Manager.
Axogen, Inc. executive Marc A. Began, EVP & General Counsel, exercised 67,500 Employee Stock Options at an exercise price of $8.16 per share on August 10, 2026, receiving an equal number of common shares. On the same date, he sold 67,500 common shares at a weighted average price of $47.345 per share in transactions executed pursuant to a Rule 10b5-1 trading plan adopted on March 11, 2026. Following the option exercise, 22,500 options from this grant remained outstanding, expiring on March 1, 2033, under a vesting schedule that completes on March 1, 2027.
Axogen, Inc. director Amy McBride exercised an employee stock option for 13,353 shares of common stock at an exercise price of $14.85 per share and on the same date sold 13,353 shares of common stock at a weighted average price of $48.423 per share. The sale was effected under a Rule 10b5-1 trading plan adopted on May 12, 2026. All shares underlying the option had been fully vested since May 14, 2018.
Axogen, Inc. director Kathy Johnson Weiler reported selling 14,150 shares of common stock on August 7, 2026 in a sale classified as an open market or private transaction. The weighted average sale price was $45.298 per share, with individual trades ranging from $44.43 to $46.47. Following this transaction, the reporting person held 0 shares directly. The sale was effected pursuant to a Rule 10b5-1 trading plan adopted on May 8, 2026.
Vanguard Capital Management LLC, together with certain affiliated entities and business divisions, reports beneficial ownership of Axogen Inc common stock on an amended Schedule 13G. The group reports beneficial ownership of 2,654,445 shares of common stock, representing 4.99% of the outstanding class.
Vanguard Capital Management has sole voting power over 396,497 shares and sole dispositive power over 2,654,445 shares, with no shared voting or dispositive power. The filing notes that this stake is held across Vanguard funds and managed accounts, and that no other single person has an interest in more than 5% of the class through these holdings.
Axogen, Inc. reported strong top-line growth but a GAAP loss for the period. Revenue was $69,731 (in thousands) for the quarter ended June 30, 2026, up 23.1% year over year, and $131,188 (in thousands) for the first six months, up 24.7%. Quarterly gross margin was 72.7%, slightly below 74.2% a year earlier as higher-cost biologic Avance products and longer grafts increased product costs.
The company posted a quarterly net loss of $1,516 (in thousands) and a six‑month net loss of $21,100 (in thousands), largely driven by a $16,849 (in thousands) loss on extinguishment of debt tied to the January 2026 payoff of its Oberland credit facility. Net proceeds of $133,252 (in thousands) from a 4.6 million‑share equity offering at $31.00 per share were used to pay a $69,707 (in thousands) payoff amount and terminate the facility, eliminating $48,387 (in thousands) of long‑term debt and related derivatives.
Cash, cash equivalents and investments rose to $111,412 (in thousands) at June 30, 2026, from $41,528 (in thousands) at year‑end, and the current ratio improved to 6.6x. Operating cash flow turned positive at $8,786 (in thousands). Operating expenses increased 32.4% year to date to support sales expansion, higher stock‑based compensation of $15,609 (in thousands), and clinical programs such as Nerve‑RESTORE. Subsequent to quarter‑end, Axogen invested $7,000 (in thousands) in Trace Biosciences, gaining a minority stake and limited right of first refusal on nerve‑specific imaging technology.
Axogen reported strong second-quarter 2026 growth, with revenue of $69.7 million, up 23.1% from $56.7 million a year earlier, driven by broad-based gains across Extremities, Oral Maxillofacial & Head and Neck, and Breast, where breast revenue grew more than 50% year over year. Gross margin was 72.7% versus 74.2% as mix shifted toward faster-growing breast procedures. The company posted a GAAP net loss of $1.5 million, or $0.03 per share, compared with $0.6 million of income, while adjusted net income rose to $7.3 million and Adjusted EBITDA was $8.4 million.
Through the first half of 2026, Axogen generated $4.1 million of free cash flow versus a negative $7.2 million a year earlier, ended June 30 with $113.4 million in cash, restricted cash and investments, and eliminated long‑term debt after recording a $16.8 million loss on extinguishment. The company also raised equity, increasing shares outstanding to 53.7 million. Management highlighted publication of the REPOSE study, initiation of the Nerve‑RESTORE trial, and a minority stake in Trace Biosciences to support nerve-specific imaging. Full‑year 2026 guidance now calls for at least 24% revenue growth, or $279 million, gross margin of at least 73%, and positive free cash flow.